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ABSTRACT
Objectives: Cervical cancer is the second most common type of cancer for women worldwide with a great proportion 
proved to be related to human papillomavirus (HPV) infection. As infection with HPV is the strongest risk factor for cervical 
neoplasia, detection of HPV genotypes in cervical and vaginal specimens of women with normal and abnormal cytology 
seems to be of paramount importance in cervical cancer screening. The objective of the study is to evaluate the prevalence 
and HPV genotypes among women with normal or abnormal Pap smear tests.
Material and methods: This retrospective study was conducted in a tertiary care university hospital in western Turkey. 
A total of 201 patients in whom both HPV typing and Pap test was performed between 2012 and 2016 in our obstetrics and 
gynecology department were enrolled in this study. Clinical and laboratory data were obtained for all participants. Cervical 
smears of the patients were classified by the Bethesda system and HPV analyses were done using the polymerase chain 
reaction (PCR) method. 
Results: This study included 201 women, 72 of whom had normal and 129 of whom had abnormal Pap smear results. HPV 
DNA was detected in 91 (45.2%) of the 201 investigated women. Out of 72 patients with normal cervico-vaginal cytology, 
HPV positivity was detected in 35 (49%) patients, whereas 33 (35%) patients out of 94 with ASCUS , 18 (62%) patients 
out of 29 with LSIL and 5 (83%) patients out of 6 with HSIL had HPV positivity. Out of 35 HPV positive women that had 
normal pap test results, 25 (75%) were found to have high risk HPV (HR-HPV) genotypes. In women with ASCUS, LSIL 
and HSIL, HR-HPV genotype rates were found to be 94%, 89% and 100% respectively. The most common identified HPV 
types were HPV58, HPV16, HPV31, HPV33, HPV11 and HPV35.
Conclusions: The frequency of HPV infection was found to be higher in our study compared to previous reports. Moreover, 
although HR-HPV genotypes were also detected in patients with normal cervical cytology, a majority of patients with 
HR-HPV genotypes were associated with abnormal cervical smear cytology including high rates of atypical squamous cells 
of undetermined significance, low-grade squamous intraepithelial lesion, and high-grade squamous intraepithelial lesion. 
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INTRODUCTION
Cervical cancer (CC) is the second most common cancer 
in women worldwide and the fourth-most common cause of 
death from cancer in women [1]. There is a large difference in 
terms of mortality and morbidity rates of CC in developing 
and developed countries because CC cases have been sig-
nificantly reduced in developed countries due to the imple-
mentation of effective screening programmes [2]. Based on 
the difficulties in implementing cytology-based screening 
tools in developing countries like Turkey, the burden of di-
sease remains very high, pointing to the need to engage and 
educate the broader public on prevention of CC [3].
Cervical cancer is a preventable disease because hav-
ing a relatively long lead time and in general precancer-
ous lesion slowly progress through recognizable stages 
before transforming into invasive disease. If the disease 
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could be identified before progression to advanced stages, 
it can nearly almost be regarded as curable [4]. Today, 
by epidemiologic and molecular investigations, it is well 
established that a persistent oncogenic or so-called hu-
man papillomavirus (HPV) infection is the leading cause in 
the development of CC [5–7]. Nearly > 90% of all CCs are 
reported to be associated with this circular, double-stranded 
oncogenic virus [8].
HPV is an intraepithelial virus from the papillomavirus 
family that affects the human skin and the moist membranes 
that line the body and is passed between people through 
skin-to-skin contact. More than 100 different papilloma fa-
mily members have been reported to exist, and in humans, 
these are responsible for a distinct variety of benign and 
malignant conditions. Although genital HPV types have been 
subdivided into high-risk (HR-HPV) types (frequently asso-
ciated with invasive CC) and low-risk (LR-HPV) types (found 
mainly in genital warts), there is still no consensus on catego-
rization of many HPV subtypes with low prevalence accord-
ing to CC risk. Current epidemiologic data identifies 15 HPV 
types as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 68, 73, and 82) and 12 types (6, 11, 40, 42, 43, 44, 54, 61, 
70, 72, 81, and CP6108) as low-risk types [9]. Moreover, infec-
tion with two specific high-risk HPVs (HPV-16 and HPV-18) 
is reported to be linked with 90% of all uterine cervical can-
cers, and more than half of other anogenital tumors, and 
a small percentage of head and neck tumors [10]. 
Apart from HPV testing, cytology-based screening 
which is known as Papanicolaou-stained cervical smear 
(Pap smear or Pap test) can also be used for CC screening. 
Abnormal results in Pap test includes atypical squamous 
cells of undetermined significance (ASCUS), low-grade 
squamous intraepithelial lesion (LSIL), high-grade squa-
mous intraepithelial lesion (HSIL), atypical glandular cells 
not otherwise specified (AGC-NOS) and squamous cell 
carcinoma [11]. Atypical glandular cells of undetermined 
significance (AGUS) term is eliminated to avoid confusion 
with ASCUS according to 2001 Bethesda system [11, 12]. 
Noncancerous conditions can also be found in Pap test 
including infections and inflammation. Although Pap test 
is acknowledged worldwide as being the most successful 
cancer screening test, HPV cotesting has markedly improved 
the ability to detect severe cervical dysplasia and provided 
better prevention against the development of CC. The objec-
tive of this research is to determine the frequency of distinct 
HPV genotypes in cervical discharge and its relation with 
cervico-vaginal cytology.
MATERIAL AND METHODS
Material
This retrospective study was performed on 201 patients 
[median age 42 years (min-max: 20–75)] in whom both 
HPV typing and Pap test was performed between 2012 and 
2016 in obstetrics and gynecology department of Canakkale 
18 Mart University, Turkey. After the approval from the same 
university’s Institutional Ethics Board, we used the hos-
pital’s electronic database which contains multiple data 
fields on demographic, clinical and laboratory variables for 
patients. The study was conducted in accordance with the 
guidelines of the Helsinki declaration.
Women with intact uterus with distinct gynecologic 
complaints including post-coital bleeding, dyspareunia, 
lower abdominal pain with no past history of gynecologic 
malignancy were included in the present study. Exclusion 
criterias were as follow; women below age of 20, current 
pregnancy, history of cervical conization and uterin prolap-
sus. Cervical smears were prepared by using cervical brush, 
fixed in 95% alcohol and stained by conventional meth-
ods. Cervical smears of the patients were examined under 
the microscope and classified by the Bethesda system [11] 
in the following categories: Normal, ASCUS, LSIL and HSIL. 
DNA isolation and HPV genotyping
Total genomic DNA was extracted from cervicovaginal 
smear samples by using the commercial QIAamp Blood 
and Tissue Kit (QIAGEN Inc., Hilden, Germany) according 
to the manufacturer’s protocol [13]. The target HPV geno-
typing was done after total genomic DNA isolation from 
cervicovaginal smear samples for each patient. Briefly HPV 
genotyping performed by the F-HPV typing™ multiplex PCR 
(Molgentix SL, Barcelona, Spain). The assay uses 16 specific 
primers amplifying within E6 and E7 regions of the HPV ge-
nome and permits the detection of 13 high risk genotypes 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and two 
low-risk genotypes (6 and 11). The presence of DNA of these 
HPV subtypes were detected by multiplex PCR amplification 
using type specific primers [14, 15]. 
For the multiplex PCR, in a total of 25 μL reagent mix-
tures contained 5 μL f-HPV PCR master mix that contained 
5 U hot start taq DNA polymerase enzyme, 15 μL primers 
mix and 5 μL target DNA were used for the amplification 
of target genes. The amplification conditions were; 96°C 
for 2 min for initial denaturation and holding phase cycles 
and in a total of thirty-five amplification cycles (ten and 
twenty-five tandem repeated sequences) were performed 
in the current genotyping procedure. Ten cycles included 
denaturation at 94°C for 30 s, annealing at 64°C for 40 s and 
extension at 70°C for 30 s tandemly followed by twenty-five 
cycles included denaturation at 90°C for 30 s, annealing at 
60°C for 40 s and extension at 70°C for 30 min. In the final 
phase, the temperature was maintained at 60°C for 30 min 
for polymerization of incomplete fragments. The PCR am-
plicons were separated and detected in terms of their size 
by using capillary electrophoresis.
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Statistical analysis
Statistical analysis was done with SPPS version 19 (SPSS 
Inc., Chicago, IL, USA) software. Data were expressed as per-
centages of the mean or as genotype frequency. Chi-square 
test was used to compare categorical measurements be-
tween the groups. The statistical significance level was ac-
cepted as 0.05.
RESULTS
Out of 201 women included in the present study, HPV 
DNA was detected in 91 (45.2%) women. The median ages 
of HPV positive and negative subjects were 40 (min–max: 
20–75) and 44 (min–max: 22–73) years respectively. Ac-
cording to cytological screening, 72 patients had normal 
cytologic findings, 94 patients had ASCUS, 29 had LSIL and 
6 had HSIL. HPV positivity was detected in 35 (49%) patients 
with normal cervico-vaginal cytology, whereas 33 (35%) 
patients with ASCUS, 18 (62%) patients with LSIL and 5 (83%) 
patients with HSIL had HPV positivity (Tab. 1). HPV positivity 
was found to be related to abnormal cytologic test results 
(p = 0.016)
The most common identified HPV types were HPV58, 
HPV16, HPV31, HPV33, HPV11 and HPV35. Twenty-seven 
(27.4%) women had mixed HPV types. Table 2 shows all HPV 
types encountered in study population.
Women with positive HPV DNA was subdivided into 
two groups including HR-HPV [n = 77 (84.6%)] and LR-HPV 
[n = 14 (15.4%)]. Pap tests of women were evaluated accord-
ing to these risk groups. Out of 35 HPV positive women with 
normal Pap test results, 25 (75%) had HR-HPV genotypes. In 
women with ASCUS, LSIL and HSIL, HR-HPV genotype rates 
were found to be 94%, 89% and 100% respectively (Tab. 3). 
According to HPV infection risk, cervical dysplasia (HSIL) 
rates were found to be elevated in HR-HPV subtype group 
(p = 0.047).
DISCUSSION
Our study population consisted of women with various 
genital complaints and nearly half of the study participants 
(45.2%) presented HPV positivity which was significantly 
higher compared to studies from Turkey [16, 17] and several 
western countries [18, 19] and similar to some developing 
countries including Latin America and the Caribbean [20, 21]. 
Table 1. Relationship between cytological screening of cervical Pap smears and Human Papillomavirus (HPV) test results
Human Papillomavirus (HPV)
Positive [n, %] Negative [n, %] Total [n, %] p
Normal 35 (49) 37 (51) 72 (100)
0.016
ASCUS 33 (35) 61 (65) 94 (100)
LSIL 18 (62) 11 (38) 29 (100)
HSIL 5 (83) 1 (17) 6 (100)
ASCUS — atypical squamous cells of undetermined significance; HSIL — high-grade squamous intraepithelial lesion;  LSIL — low-grade squamous intraepithelial lesion
Table 2. Prevalence of human papillomavirus (HPV) types
HPV type n %
HPV6 10 11
HPV 11 4 4.4
HPV 16 15 16.5
HPV 31 5 5.5
HPV 33 5 5.5
HPV 35 4 4.4
HPV 45 1 1.1
HPV 51 2 2.2
HPV 52 2 2.2
HPV 56 1 1.1
HPV 58 13 14.3
HPV 59 2 2.2
Mix* 27 29.6
Total 91 100
*Mix HPV types: 6/16; 6/58; 6/59; 6/56/59; 6/39/58; 11/16; 16/39; 16/52; 16/68; 
59/68; 18/51; 39/52; 51/58; 52/68; 58/59; 56/58
Table 3. Cytological screening of cervical Pap smears according to HPV infection risks
High-risk HPV [n, %] Low-risk HPV [n, %] Total [n, %] p
Normal 25 (71) 10 (29) 35 (100)
0.047
ASCUS 31 (94) 2 (6) 33 (100)
LSIL 16 (89) 2 (11) 18 (100)
HSIL 5 (100) 0 (0) 5 (100)
ASCUS — atypical squamous cells of undetermined significance; HSIL — high-grade squamous intraepithelial lesion;  LSIL — low-grade squamous intraepithelial lesion
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Apart from these elevated rates of HPV infection, we also 
found that HPV 16 and HPV 58 was associated with common 
abnormal cervical smear test results including high rates 
of ASCUS, LSIL and HSIL. These elevated rates of abnormal 
cytologic test results that has found to be linked with HPV 
positivity indicates that HPV is a major risk factor in the 
development of CC.
Globally CC is the third frequent cancer for woman fol-
lowing breast cancer and colorectal cancer [22]. It is a unique 
cancer because of being preventable in nature due to suc-
cessful applications of cervical smear screenings. In de-
veloped countries where screening activities commonly 
applied success rates are particularly impressive whereas in 
developing countries CC still causes significant number of 
deaths [23]. According to Turkey cancer control programme, 
CC is the 10th most frequently observed cancer in women 
following breast, thyroid, colorectal, uterus corpus, lung, 
stomach, ovary, non-Hodgkin lymphoma and brain cancers 
[3]. Although it can be speculated that CC does not represent 
a serious threat in Turkey compared with other cancers, 
a global CC screening program with cervical smear test has 
been applied by department of cancer of Ministry of Health 
since 1992 [24]. In accordance with global scientific trends, 
national screening programme for CC was changed after 
two decades and HPV testing was implemented as a primary 
screening for CC [23]. According to the Renewed National 
Cervical Screening program, HPV test once in 5 years and 
smear evaluation in HPV positive cases is recommended to 
every women between ages of 30–65 [3]. In this context, it 
is important for centers to present their own results to the 
scientific community and exchange knowledge and practice 
on preventing CC development.
The results of the present study demonstrated that 
HPV16, HPV 58, HPV6, HPV31, HPV33 and HPV11 were the 
six most prevalent types in our study population. In a study 
by Ari et al. [25] the most common HPV types that infect the 
genital area was reported to be HPV16 and HPV6. In another 
study from Turkey, Yavuzer and colleagues [26] investigated 
the prevalence of HPV DNA and reported the distribution 
of HPV types among women with cervical cancerous and 
precancerous lesions. The authors stated that the most com-
mon three HPV types were as follows; HPV6, HPV11 and HPV 
31. Analysis of existing studies in different countries regard-
ing the types of HPV infection in abnormal cervical scrapes 
also demonstrated similar results. Finan et al. [27] reported 
that by using the consensus primer set MY09/MY11 HPV 
types 6, 11, 16, 18 and 33 were the most common detected 
HPV genotypes in endocervical and vaginal scrapes of wom-
en with abnormal cytology and also in those with normal 
cytology. In a study by Antonishyn et al. [28] it was found 
that the most commonly encountered HPV genotype in 
patients with cervical intraepithelial neoplasia grade 2 or 
3 was HPV16 (46.7%) which was followed by HPV-31 (14.7%) 
and HPV-18 (3.9%). Apart from these studies, a recent study 
from Africa in which the prevalence of HPV infection, hu-
man immunodeficiency virus (HIV) infection, and cervical 
cytologic abnormality rates were investigated in women 
who were admitted to a sexually transmitted infections 
clinic demonstrated that most common HPV genotypes 
were 52,58 and 16. Moreover all of the HIV positive women 
were reported to be co-infected with HPV [29].
The incorporation of HPV cotesting into cervical 
screening programmes has undoubtedly improved the 
ability to detect cervical dysplasia/neoplasia and provided 
better prevention against CC. This algorithm is also associ-
ated with somewhat worsened specificity and an elevated 
risk for not detecting new glandular lesions. In a study by 
Al-Awadhi and colleagues [30] the prevalence and type 
specific distribution of HPV in women with normal cervi-
cal cytology was investigated. The authors reported rela-
tively low rates (2.4%) of HPV positivity in their patient 
population and these low rates were attributed to unique 
sociodemographic and sexual behaviour characteristics 
of the country. In a study from Turkey, although HPV DNA 
was found to be positive in 20% of the women with normal 
cervical cytology, it was positive in 36% of women with 
abnormal cervical cytology [17]. The reason for this low 
HPV rates in women with abnormal cytology explained by 
technical or sampling biases. In our study, we found that 
high-risk HPV types were associated with increased cervical 
dysplasia rates in cervico-vaginal smears and 32.5% (25/77) 
of HR-HPV positive women had normal Pap tests. These 
patients with normal Pap tests and HR-HPV types must 
be regularly followed up in accordance with international 
guidelines. This is because of the fact that women with 
HR-HPV positivity and negative Pap smear tests for in-
traepithelial lesions are at a high risk of having serious 
HPV induced lesions in the future [31]. Delayed follow-up 
may have jeopardized these patients at risk for serious 
epithelial changes. For this reason, in women with slight 
cell alterations (such as ASCUS and LSIL) follow-up testing 
is commonly recommended. In women with HSIL, colpos-
copy with endocervical sampling has been considered 
the best management [32]. Increased cervical dysplasia 
rates observed in HR-HPV infections lend support to the 
suggestion that differences in HPV type may indeed cor-
relate with differences in biological potential and risk for 
invasion in LSIL and HSIL lesions.
This study showed that the HPV infection rate in Turkey 
is more common compared with previous studies. Moreover, 
based on the presence of high rates of HR-HPV genotypes 
even in women with normal cervico-vaginal cytology neces-
sitates more close follow-up with immediate reference to col-
poscopy. Therefore, despite the fact that current preventive 
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vaccines significantly reduce but not eliminate the risk of 
cervical cancers and other premalignant diseases related to 
HPVs, there is a need for effective immunological treatment 
of HPV and related disorders. 
Limitations
We recognize that there are limitations to our study 
design. First, our study population is relatively small and 
limited to the patients that were admitted to a single center, 
therefore conclusions from the present study could not be 
generalized further. Moreover, despite this limited number 
of subjects, we found significant differences between sub-
group analysis. Second, the retrospective design of the study 
did not permit us to adequately analyze the prognostic 
variables and management. However, since the goal of the 
present study was to examine the relationship between 
HPV and cervical cytological associations, there was no way 
to overcome the limitations which necessarily accompany 
a retrospective design. Third, although universal colposcopy 
is not part of standard clinical care, it would be noteworthy 
if colposcopic examination with endocervical assessment 
had taken place. 
CONCLUSIONS
1. HPV DNA testing with cervicovaginal smear analysis 
can improve the detection rate of cervical intra epithe-
lial lesions.
2. HPV infection is more prevalent than expected among 
women in Turkey, which indicates higher attention to 
prevention and screening in the gynecology and ob-
stetrics clinics.
3. High risk HPV types have great value in determining 
high grade of cervical intraepithelial neoplasia and sub-
sequent cervical cancer development. 
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